Ironwood Pharmaceuticals (NASDAQ:IRWD) Upgraded at Leerink Partnrs

Leerink Partnrs upgraded shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) to a hold rating in a research report released on Monday morning, Zacks.com reports. Leerink Partnrs also issued estimates for Ironwood Pharmaceuticals’ Q3 2024 earnings at $0.03 EPS, Q4 2024 earnings at $0.09 EPS, FY2024 earnings at $0.10 EPS, Q1 2025 earnings at $0.03 EPS, Q2 2025 earnings at $0.03 EPS, Q3 2025 earnings at $0.04 EPS, Q4 2025 earnings at $0.04 EPS, FY2025 earnings at $0.13 EPS and FY2026 earnings at $0.42 EPS.

Other analysts have also recently issued research reports about the company. Craig Hallum lowered their price target on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a buy rating for the company in a research report on Friday, August 9th. Wells Fargo & Company lowered their price target on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an overweight rating for the company in a research report on Friday, August 9th. StockNews.com raised Ironwood Pharmaceuticals from a hold rating to a buy rating in a research report on Tuesday, July 16th. Leerink Partners started coverage on Ironwood Pharmaceuticals in a research report on Monday. They set a market perform rating and a $5.00 price target for the company. Finally, Capital One Financial cut Ironwood Pharmaceuticals from an overweight rating to an equal weight rating and lowered their price target for the stock from $12.00 to $4.00 in a research report on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of Moderate Buy and a consensus target price of $13.57.

Ironwood Pharmaceuticals Price Performance

Ironwood Pharmaceuticals stock opened at $4.35 on Monday. The stock has a market capitalization of $694.87 million, a price-to-earnings ratio of -0.64 and a beta of 0.49. Ironwood Pharmaceuticals has a 1-year low of $3.79 and a 1-year high of $15.70. The business has a fifty day moving average price of $5.62 and a 200-day moving average price of $6.97.

Insider Activity at Ironwood Pharmaceuticals

In related news, insider Minardo John sold 9,910 shares of Ironwood Pharmaceuticals stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $4.27, for a total value of $42,315.70. Following the completion of the transaction, the insider now owns 284,661 shares in the company, valued at approximately $1,215,502.47. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 12.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. First Eagle Investment Management LLC boosted its holdings in Ironwood Pharmaceuticals by 11.1% in the 4th quarter. First Eagle Investment Management LLC now owns 907,225 shares of the biotechnology company’s stock worth $10,379,000 after buying an additional 90,636 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Ironwood Pharmaceuticals by 244.8% during the 1st quarter. Russell Investments Group Ltd. now owns 777,847 shares of the biotechnology company’s stock worth $6,775,000 after purchasing an additional 552,227 shares during the last quarter. Eventide Asset Management LLC acquired a new position in shares of Ironwood Pharmaceuticals during the 4th quarter worth approximately $8,472,000. Norges Bank acquired a new position in shares of Ironwood Pharmaceuticals during the 4th quarter worth approximately $9,321,000. Finally, Entropy Technologies LP acquired a new position in shares of Ironwood Pharmaceuticals during the 1st quarter worth approximately $693,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.